|
|
 |
|
|
|
|
143. J. Norregard, et al. Long Term Nicotine Substitution After Application of a 16 Hour Nicotine Patch in Smoking Cessation. Eur. J. Clin. Pharmacol. 43: 57, 1992. |
|
|
|
|
|
|
|
|
144. J. Rose, et al. Four Week Tolerability of a Transdermal Nicotine Patch for Smoking Cessation. Pharm. Res. 8 (No. 10, Suppl.): S209, 1991. |
|
|
|
|
|
|
|
|
145. P. Denniston. Physicians' GenRx. Data Pharmaceutica, Smithtown, NY, 1993, p. II-865. |
|
|
|
|
|
|
|
|
146. R. Gale, et al. Belg. Patent 0905568 (1987). |
|
|
|
|
|
|
|
|
147. P. Plezia, et al. Pharmacotherapy 9: 2, 1989. |
|
|
|
|
|
|
|
|
148. F. Holley and C. Van Stennis. Br. J. Anaesth. 60: 608, 1988. |
|
|
|
|
|
|
|
|
149. R. Caplan, et al. J. Am. Med. Assoc. 261: 1036, 1990. |
|
|
|
|
|
|
|
|
150. A. Fleckenstein, et al. A New Group of Compatible Calcium Antagonists. Fluegers Arch. 307: 25, 1969. |
|
|
|
|
|
|
|
|
151. W. Frishman, et al. Calcium Channel Blockers in Systemic Hypertension. Curr. Probl. Cardiol. 12: 287, 1987. |
|
|
|
|
|
|
|
|
152. D. Swanson, et al. Nifedipine Gastrointestinal Therapeutic System. The American J. of Med. 83 (Suppl. 6B): 3, 1987. |
|
|
|
|
|
|
|
|
153. A. Kydonieus, unpublished data. |
|
|
|
|
|
|
|
|
154. D. Hillerman, et al. Conversion from Sustained-Release to Immediate-Release Calcium Entry Blockers: Outcome in Patients with Mild-to-Moderate Hypertension. Clinical Therapeutics 15: 1002, 1993. |
|
|
|
|
|
|
|
|
155. J. Hinnan and Z. Grapes. Formulary Management Activities in Georgia. Pand T. 17: 475, 1992. |
|
|
|
|
|
|
|
|
156. R. Plumridge, et al. The Effect of Hospital Formularies. Drug Intell. Clin. Pharm. 18: 652, 1984. |
|
|
|
|
|
|
|
|
157. M. Testa. Parallel Perspectives on Quality of Life During Antihypertensive Therapy. J. Cardiovascular Pharmac. 21 (Suppl. 2): 518, 1993. |
|
|
|
|
|
|
|
|
158. W. Frishman, et al. The Nifedipine Gastrointestinal Therapeutic System in the Treatment of Hypertension. Am. J. of Cardiology 64: 65F, 1989. |
|
|
|
|
|
|
|
|
159. Strategic Research Institute, On the Cutting Edge of Drug Delivery Systems Conference, October 1994. |
|
|
|
|
|
|
|
|
160. Special Report on Drug Delivery. Med. Ad. News August 1993: 10. |
|
|
|
|
|
|
|
|
161. Scrip No. 1888. P. J. Publications Ltd., January 14, 1994, p. 13. |
|
|
|
|
|
|
|
|
162. T. Franz, et al. Transdermal Delivery, in Treatise on Controlled Drug Delivery. A. Kydonieus, Ed. Marcel Dekker, New York, 1992, p. 341. |
|
|
|
|
|
|
|
|
163. A. Obermayer, et al. Transdermal Pharmaceuticals Containing Amines and Non-polar, Non-volatile Solvents. Europ. Patent Appl. EP267051 (1989). |
|
|
|
|
|
|
|
|
164. D. Patel and C. Ebert. Method for Reducing Skin Irritation Associated with Drug/Penetration Enhancer Compositions. U.S. Patent 4855294 (1989). |
|
|
|
|
|
|
|
|
165. S. Govil and P. Kohlman. Transdermal Delivery of Nicotine. U.S. Patent 4908213 (1990). |
|
|
|
|
|
|
|
|
166. A. Amkraut and J. Shaw. Prevention of Contact Allergy by Coadministration of a Corticosteroid with a Sensitizing Drug. U.S. Patent 5000956 (1991). |
|
|
|
|
|
|
|
|
167. Rockefeller University. Glucocorticoid Carboxylic Acid Ester for Suppressors of Cutaneous Delayed Hypersensitivity. PCT Inst. Appl. W08809175. |
|
|
|
|
|